Rethinking smoking assessment in head and neck squamous cell carcinoma: are we missing something?
Frontiers in Oncology · 01.07.2026 · 16
DOI: 10.3389/fonc.2026.1887251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 01.07.2026. Verfasst von Riccardo Gili und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Tobacco exposure is a major determinant of risk and clinical outcomes in head and neck squamous cell carcinoma (HNSCC). Although pack-years have long represented the standard metric for quantifying smoking exposure, increasing evidence suggests that this approach incompletely captures the biological and clinical heterogeneity of tobacco-related risk.
Discussion
Recent epidemiological and clinical studies demonstrate that smoking duration rather than its intensity or cumulative pack-years measures is a stronger predictor of HNSCC risk and overall survival, particularly among long-term smokers. Regarding cumulative metrics, metrics like log cigarette-years have shown a better prognostic role when compared with pack-years. Beyond cumulative or duration-based models, smoking cessation and the use of alternative tobacco products substantially influence HNSCC risk and clinical outcomes. While smoking cessation is associated with a progressive reduction in risk and improved survival, active smoking at diagnosis is consistently associated with inferior treatment response. In parallel, non-cigarette tobacco products—including cigars, pipes, and smokeless tobacco—have been shown to independently increase HNSCC risk, are rarely incorporated into exposure models. The growing use of alternative nicotine-containing products, often in combination with cigarette smoking, further complicates risk assessment, as their long-term carcinogenic and immunomodulatory effects remain incompletely characterized.
Conclusion
Pack-years–based models alone are insufficient for accurate risk stratification in HNSCC and realize integrated models including smoking duration assessment may improve prognostic and predictive accuracy, supporting more personalized treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- Medical Oncology, Department of Internal Medicine and Medical Specialties, University of Genova, Genoa, Italy.
- Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia; Unit of Medical Oncology, Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili, Brescia, Italy.
- Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Roma, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Zitieren
APA
Gili, R., Lorini, L., Smussi, D., Di Bello, A., Bossi, P., & Resteghini, C. (2026). Rethinking smoking assessment in head and neck squamous cell carcinoma: are we missing something?. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1887251
Vancouver
Gili R, Lorini L, Smussi D, Di Bello A, Bossi P, Resteghini C. Rethinking smoking assessment in head and neck squamous cell carcinoma: are we missing something?. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1887251
BibTeX
@article{Gili2026,
author = {Gili, Riccardo and Lorini, Luigi and Smussi, Davide and Di Bello, Armando and Bossi, Paolo and Resteghini, Carlo},
title = {Rethinking smoking assessment in head and neck squamous cell carcinoma: are we missing something?},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1887251}
}
EUVIMED